SPOTLIGHT: Levaquin exclusive extended


The FDA has extended J&J's marketing exclusive for the antibiotic Levaquin based on its effectiveness among children. The decision--which was based on five pediatric studies--extends J&J's patent protection to June, 2011. Release

Suggested Articles

Merck’s TIGIT-blocking prospect and PD-1 med Keytruda shrank tumors in 29% of lung cancer patients who had never tried a checkpoint inhibitor.

Merck's HIF-2α inhibitor, picked up in its $1 billion Peloton buyout, shrank kidney tumors in 36% of patients and showed promise in other tumors, too.

Amunix reported that a single dose of its lead T-cell engager caused caused large HER2-positive tumors to shrink in mice.